Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis
about
Protective efficacy of a sulfated sialyl lipid (NMSO3) against human rotavirus-induced diarrhea in a mouse modelPassive immunity against human pathogens using bovine antibodies.Rotavirus disease and its prevention in infants and children.Recurrent and Sustained Viral Infections in Primary Immunodeficiencies.Vaccine-acquired rotavirus in infants with severe combined immunodeficiencySialic acid glycoproteins inhibit in vitro and in vivo replication of rotaviruses.Systemic rotavirus infection.Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.Immune mediators of rotavirus antigenemia clearance in mice.Noroviruses: The leading cause of gastroenteritis worldwideVibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.Rotavirus vaccines: an overview.Past, present, and future technologies for oral delivery of therapeutic proteins.Human viral gastroenteritis.Rotavirus vaccine administered parenterally induces protective immunityRecovery from chronic rotavirus infection in mice with severe combined immunodeficiency: virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes.Persistent rotavirus infection in mice with severe combined immunodeficiency.Rotavirus gene structure and function.Rotavirus vaccines: how they work or don't work.Pneumocystis carinii antigen detection in rat serum and lung lavage.Monoclonal antibody assay for detection of double-stranded RNA and application for detection of group A and non-group A rotavirusesHomotypic and heterotypic antibodies for prevention of experimental rotavirus gastroenteritis.Murine intestinal antibody response to heterologous rotavirus infection.Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Oral passive IgY-based immunotherapeutics: a novel solution for prevention and treatment of alimentary tract diseasesTargeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications.Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humansNorovirus infection in primary immune deficiency.Protease inhibitors suppress the in vitro and in vivo replication of rotavirus.Gastrointestinal problems in the immunosuppressed patient.Lipid composition and amino acid uptake during rotavirus infection and protection with trypsin inhibitor in malnourished infant mice.Oral immunoglobulin treatment improved intestinal permeability in children with active Crohn's disease.
P2860
Q28345176-81A3A3F4-2536-4DDA-BD02-8A509B5D3BF0Q33640433-1B4F2D6A-A32B-452C-89BA-D90428B0FB57Q33771355-7B88EED5-8146-4D37-8131-D1EF2CA42BC9Q33809611-EB8559BA-16C1-4296-9ACD-7C8E176146FFQ33920990-76F48EC2-E50E-4523-83FE-D8BC422EA17CQ34555040-5DA913C2-8F0E-4C64-908E-18FABA8E8940Q34659711-60B25491-11AA-4CA8-B20B-105AB9FDFBF3Q34711833-EF003142-D945-4680-9ECB-1FD1BF32083EQ35140279-650B5B2D-B765-4810-A6AB-645D0B938493Q35148970-54D8C301-8D3A-4E80-B834-748A7CECBFEDQ35229428-526317AA-879A-47CA-B01F-B5452958AD38Q35371774-E890A82B-6154-4781-AD1C-E403A8B23213Q36232650-3B3A6610-B39F-4E41-BE06-933EDA12A9FDQ36634738-F195C6D9-6D1F-4113-8718-9BD28266FC39Q36654407-D090CBF5-8EE8-4639-A3C2-69ED05247A49Q36783022-44DC0C7A-8C35-418C-A3FF-D349BB9B6E3BQ36919482-A75605F9-100A-4170-9C50-21DEC21DD4A7Q37055891-54A892CB-DF0A-461E-AFC7-DB880A9B71D0Q37081817-0AC59B9C-FD3E-4420-8884-8ACB921C648BQ37153926-64FDDFDA-5D12-418E-BC5A-14B2B1DE6579Q37166863-84C1DD8D-7FF4-48B2-9709-3C789CD90F0CQ37213643-47BE5A13-0221-452C-829E-EDF51C787FFBQ37241347-DD8412CA-D0FB-4410-B4E5-34350BE961D5Q37901418-88E3D42B-EBF4-4F6D-A44A-8BDCB2A5C8A6Q38072598-1067723A-0FE4-48F5-AFD9-9DB769A245B0Q38074099-B6E31C4F-83FA-44F2-93C7-E0E88F44DBFFQ38323786-2A67D9B8-3D43-491C-973D-B0511D79E9EDQ38423920-0B50B2E1-9321-4132-AB76-81DA3BDAB3E9Q39167685-3860D19F-B11B-4337-AEC9-466A85469854Q41018426-96A072C2-5956-40BE-89D0-86EB08E70A10Q41735464-C019DA73-5EB6-47EE-9A90-A7D9EA532C43Q41838668-ACFD42B6-E8A9-4327-8AB4-EB800D43E12CQ51178308-694B67A6-ECBF-46F5-8428-95B360BB1412
P2860
Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis
description
1985 nî lūn-bûn
@nan
1985 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Oral administration of human s ...... inetic and functional analysis
@ast
Oral administration of human s ...... inetic and functional analysis
@en
Oral administration of human s ...... inetic and functional analysis
@nl
type
label
Oral administration of human s ...... inetic and functional analysis
@ast
Oral administration of human s ...... inetic and functional analysis
@en
Oral administration of human s ...... inetic and functional analysis
@nl
prefLabel
Oral administration of human s ...... inetic and functional analysis
@ast
Oral administration of human s ...... inetic and functional analysis
@en
Oral administration of human s ...... inetic and functional analysis
@nl
P2093
P2860
P356
P1476
Oral administration of human s ...... inetic and functional analysis
@en
P2093
G A Losonsky
J A Winkelstein
J P Johnson
R H Yolken
P2860
P304
P356
10.1172/JCI112248
P407
P577
1985-12-01T00:00:00Z